CO6430435A2 - Nuevas vacunas combinadas con células completas de pertussis y método de fabricación de las mismas - Google Patents

Nuevas vacunas combinadas con células completas de pertussis y método de fabricación de las mismas

Info

Publication number
CO6430435A2
CO6430435A2 CO11063984A CO11063984A CO6430435A2 CO 6430435 A2 CO6430435 A2 CO 6430435A2 CO 11063984 A CO11063984 A CO 11063984A CO 11063984 A CO11063984 A CO 11063984A CO 6430435 A2 CO6430435 A2 CO 6430435A2
Authority
CO
Colombia
Prior art keywords
vaccine
manufacturing
antigens
pertussis
same
Prior art date
Application number
CO11063984A
Other languages
English (en)
Inventor
Rajesh Jain
Sukhjeet Singh
Lavit Jambu
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of CO6430435A2 publication Critical patent/CO6430435A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención se relaciona con una vacuna combinada que comprende una mezcla de antígenos para protección contra enfermedades tales como difteria, tétanos, tos ferina (coqueluche) con células completas y polio. La presente invención también ser relaciona con la inclusión de uno o más antígenos en dicha vacuna combinada, para protección contra infecciones causadas por Haemophilus influenzae, virus de la hepatitis, y otros patógenos, tal que la administración de la vacuna puede inmunizar simultáneamente al sujeto contra más de un patógeno. La invención en particular se relaciona con una vacuna combinada completamente líquida y estable que comprende los antígenos indicados más arriba y con los métodos para fabricar dicha vacuna.
CO11063984A 2008-10-24 2011-05-24 Nuevas vacunas combinadas con células completas de pertussis y método de fabricación de las mismas CO6430435A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2437DE2008 2008-10-24

Publications (1)

Publication Number Publication Date
CO6430435A2 true CO6430435A2 (es) 2012-04-30

Family

ID=42119002

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11063984A CO6430435A2 (es) 2008-10-24 2011-05-24 Nuevas vacunas combinadas con células completas de pertussis y método de fabricación de las mismas

Country Status (14)

Country Link
US (1) US20110195087A1 (es)
EP (2) EP2361094A4 (es)
JP (1) JP2012506420A (es)
CN (1) CN102196817B (es)
AP (1) AP2011005700A0 (es)
AR (1) AR073957A1 (es)
BR (1) BRPI0920629A2 (es)
CA (1) CA2741393A1 (es)
CL (1) CL2011000913A1 (es)
CO (1) CO6430435A2 (es)
MA (1) MA32821B1 (es)
PE (1) PE20100365A1 (es)
RU (2) RU2504398C2 (es)
WO (1) WO2010046934A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102633898B (zh) * 2012-04-23 2013-11-27 成都欧林生物科技股份有限公司 一种Hib多糖与蛋白结合工艺的优化方法
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN106075428A (zh) * 2015-07-01 2016-11-09 北京科兴中维生物技术有限公司 一种免疫原性组合物及其制备方法
KR101864029B1 (ko) * 2015-09-16 2018-06-01 주식회사 엘지화학 다회투여량 혼합 백신 조성물
PE20200004A1 (es) * 2016-08-26 2020-01-06 Serum Institute Of India Pvt Ltd Composicion de vacuna multivalente novedosa
GEP20227386B (en) 2017-07-18 2022-06-10 Serum Institute Of India Pvt Ltd Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2020165920A1 (en) * 2019-02-12 2020-08-20 Biological E Limited Multivalent vaccine composition
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097140A (en) 1958-10-31 1963-07-09 Merck & Co Inc Preparing a mixed polio, pertussis, tetanus, and diphtheria vaccine with benzethonium chloride
US3097142A (en) 1960-03-30 1963-07-09 Merck & Co Inc Benzyl alcohol stabilized polio vaccines and production thereof
DK0835663T3 (da) 1992-05-23 2010-02-01 Glaxosmithkline Biolog Sa Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
SK283565B6 (sk) 1996-07-02 2003-09-11 Connaught Laboratories Limited Multivalentná imunogénna kompozícia a jej použitie
PE20020126A1 (es) 2000-06-29 2002-04-27 Smithkline Beecham Biolog Composicion de vacuna
KR100385711B1 (ko) 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
GB0223355D0 (en) 2002-10-08 2002-11-13 Chiron Spa Vaccine
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
KR20030069918A (ko) 2003-06-25 2003-08-27 주식회사 삼정산업 간편 조립식 파렛트 판재, 간편 조립식 파렛트 중간지지구및 간편 조립식 파렛트와 그의 제작방법
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
EP1793852A1 (en) * 2004-08-27 2007-06-13 Panacea Biotec Ltd. Inactivated poliomyelitis vaccine derived from sabin strain of polio virus
ES2387582T3 (es) 2006-09-07 2012-09-26 Glaxosmithkline Biologicals S.A. Vacuna de combinación con cantidades reducidas del antígeno del virus de la polio

Also Published As

Publication number Publication date
CL2011000913A1 (es) 2012-01-20
RU2011120309A (ru) 2012-11-27
CN102196817A (zh) 2011-09-21
PE20100365A1 (es) 2010-05-21
EP2529750A1 (en) 2012-12-05
CN102196817B (zh) 2016-04-06
RU2613295C2 (ru) 2017-03-15
EP2361094A4 (en) 2012-12-05
MA32821B1 (fr) 2011-11-01
RU2504398C2 (ru) 2014-01-20
AR073957A1 (es) 2010-12-15
CA2741393A1 (en) 2010-04-29
RU2011135761A (ru) 2013-03-10
BRPI0920629A2 (pt) 2016-01-12
US20110195087A1 (en) 2011-08-11
JP2012506420A (ja) 2012-03-15
EP2361094A1 (en) 2011-08-31
AP2011005700A0 (en) 2011-06-30
WO2010046934A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
CO6430434A2 (es) Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismas
CO6430435A2 (es) Nuevas vacunas combinadas con células completas de pertussis y método de fabricación de las mismas
WO2012093406A3 (en) A combination heptavalent vaccine
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
PH12014501133A1 (en) Compositions and methods for treating hepatitis c virus
BR112012004698A2 (pt) métodos de redução de atividade virucida em composições de pcv-2 e composições de pcv-2 com uma imonugenicidade aprimorada.
MX2023000211A (es) Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
AR092896A1 (es) Composiciones inmunogenicas
WO2010019262A3 (en) Polyvalent vaccine
CO6781540A2 (es) Protéinas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae
GT201500046A (es) Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d
BR112012033767A2 (pt) processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina.
AR080111A1 (es) Metodos y composiciones de inmunizacion
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
EA201500701A1 (ru) Способ создания вакцины против микоплазм
AR088580A1 (es) Metodos y composiciones para tratar el virus de la hepatitis c
WO2013104995A3 (en) Compositions and methods for treating viral infections
CU20190013A7 (es) Composiciones de vacunas multivalentes
MX2016001695A (es) Composiciones inmunogenas de combinacion.
BR112013021870A2 (pt) vacina contra dengue tetravalente e bivalente mista
PE20211648A1 (es) Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma
MA42317B2 (fr) Composition de vaccin combinée pour administration multiple
AR117191A1 (es) Composiciones inmunogénicas
AR089737A1 (es) Procedimiento de formulacion de una vacuna que contiene al menos dos antigenos susceptibles de adsorberse sobre el oxi-hidroxido de aluminio

Legal Events

Date Code Title Description
FC Application refused